SecBot SecBot
SECBOTREPLAY Home › Report › NVS

NVS · The Texas Court of Appeals denied Novartis's petition for writ of…

In Re Novartis Pharmaceuticals · COURT-RULING filed Apr 29, 2026 at 20:00 ET

At the news

BEARISHIMPACT 6/10

COURT-RULING filed Apr 29, 2026 at 20:00 ET

The Texas Court of Appeals denied Novartis's petition for writ of mandamus seeking to dismiss a qui tam action brought by Health Selection Group LLC under the Texas Medicaid Fraud Prevention Act. The court held that Novartis has an adequate remedy by appeal and that the costs of discovery do not justify the extraordinary remedy of mandamus. The ruling keeps the case alive for factual development, exposing Novartis to potentially massive discovery costs and litigation risk over claims that its free 'white coat marketing' services to healthcare providers constitute illegal kickbacks.

  • Novartis's petition for writ of mandamus was DENIED by the Texas Court of Appeals (15th District) on April 30, 2026.
  • The underlying qui tam action alleges Novartis engaged in unlawful marketing schemes under the Texas Medicaid Fraud Prevention Act for at least a decade.
  • The petition seeks disgorgement of 'any payment' Medicaid made as a result of alleged unlawful acts, plus civil penalties of at least $5,500 per unlawful act.
  • Novartis allegedly reaped 'hundreds of millions of dollars from Texas Medicaid' according to the plaintiff's petition.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access